Saturday, October 16, 2021

Why Syndax Pharmaceuticals Inc. (SNDX) stock is decreasing rapidly?

Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage healthcare company that focuses on an HDAC inhibitor for tumors and specializes in cancer therapies, announced the latest positive data from Phase 1 of the trial inclusive of the dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia. SNDX stock price plunged immensely adjacent to the news.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Syndax Pharmaceuticals Inc. (SNDX) shares were falling -27.92% to trade at $13.97 in the current market at the last check. The price range of the company’s shares fluctuated between $18.89 and $20.9599. SNDX’s shares have declined by -8.89% in the last five days, while they have lost -15.81% in the last month. SNDX stock has had a 50-day moving average of $22.66, which is above the 200-day moving average of $19.67. Moreover, the stock is currently trading at a RSI of 37.26.

About Syndax Interim Data.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


As of a March 12, 2021 data cutoff date, 43 patients consisting of an average of 3 therapies beforehand, inclusive of stem cell transplant, and chemotherapy, were given doses in the Phase 1 part of the AUGMENT-101 trial. 31 patients were evaluated for the efficacy of the treatment, with the remaining 12 patients not carrying either the MLLr or NPM1c mutation.

Data from the ongoing Phase 1/ 2 AUGMENT 101 trial indicates a 48% overall response rate in patients with MLLr or NPM1c, with 67% of patients who responded achieving least residual disease-negative status.

FDA granted SNDX drug designation.

FDA has also granted an orphan drug designation to Syndaxfor treatment of people effected with idiopathic pulmonary fibrosis, a potentially fatal lung disease. The orphan drugs are granted to treat rare diseases, averaging less than 200,000 patients. This grant entitles syntax with various benefits which include tax exemptions for clinical trial expenses, and marketing exclusivity.

As per company data, approximately 150,000 people could be effected by idiopathic pulmonary fibrosis and potential approval could skyrocket Syndax’s growth for the future, with the company currently evaluating the safety of the drug.

Conclusion

SNDX stock price plummeted as investors expected ground breaking news, however, SNDX interim data did not provide adequate results, with 5% of the patients facing adverse effects such as prolongation, anemia, and differentiation syndrome. Furthermore, among all patients treated, 9% of patients experienced grade 3 QT prolongation, hence shareholders were skeptical about the future of the company.

Latest news

Westwater Resources, Inc. (WWR) Stock Surging in Aftermarket, Here’s Why

Westwater Resources, Inc. (WWR), an energy materials developer, has soared 19.77% in the aftermarket trading session. As a result, WWR stock is changing hands...

Ra Medical Systems, Inc. (RMED) Stock Surging in Aftermarket

Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company, has increased 11.30% in aftermarket trading session. Consequently, RMED stock was trading at $3.25...

Payoneer Inc. (PAYO) Stock Steadily Declining in Aftermarket Despite No Reason

Payoneer Inc. (PAYO), a cross-border payment and commerce-enabling platform is trading at $8.19 at the time of the writing after declining 0.73% in aftermarket...

Why Capstone Green Energy Corp. (CGRN) Stock Dipping in Aftermarket?

Capstone Green Energy Corp. (CGRN), a company designing, assembling, and manufacturing microturbine power generation systems, has declined 7.14% in aftermarket trading session and consequently,...

Related news

Westwater Resources, Inc. (WWR) Stock Surging in Aftermarket, Here’s Why

Westwater Resources, Inc. (WWR), an energy materials developer, has soared 19.77% in the aftermarket trading session. As a result, WWR stock is changing hands...

Ra Medical Systems, Inc. (RMED) Stock Surging in Aftermarket

Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company, has increased 11.30% in aftermarket trading session. Consequently, RMED stock was trading at $3.25...

Payoneer Inc. (PAYO) Stock Steadily Declining in Aftermarket Despite No Reason

Payoneer Inc. (PAYO), a cross-border payment and commerce-enabling platform is trading at $8.19 at the time of the writing after declining 0.73% in aftermarket...

Why Capstone Green Energy Corp. (CGRN) Stock Dipping in Aftermarket?

Capstone Green Energy Corp. (CGRN), a company designing, assembling, and manufacturing microturbine power generation systems, has declined 7.14% in aftermarket trading session and consequently,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam